- Home
- PBA vs BIIB Comparison
PBA vs BIIB Comparison
Compare PBA & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBA
- BIIB
- Stock Information
- Founded
- PBA 1997
- BIIB 1978
- Country
- PBA Canada
- BIIB United States
- Employees
- PBA N/A
- BIIB N/A
- Industry
- PBA Oil & Gas Production
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- PBA Energy
- BIIB Health Care
- Exchange
- PBA Nasdaq
- BIIB Nasdaq
- Market Cap
- PBA 24.0B
- BIIB 25.1B
- IPO Year
- PBA N/A
- BIIB 1991
- Fundamental
- Price
- PBA $36.55
- BIIB $149.94
- Analyst Decision
- PBA Buy
- BIIB Buy
- Analyst Count
- PBA 1
- BIIB 26
- Target Price
- PBA $57.00
- BIIB $248.00
- AVG Volume (30 Days)
- PBA 1.6M
- BIIB 1.6M
- Earning Date
- PBA 11-05-2024
- BIIB 02-11-2025
- Dividend Yield
- PBA 5.28%
- BIIB N/A
- EPS Growth
- PBA 51.43
- BIIB 10.05
- EPS
- PBA 2.43
- BIIB 11.06
- Revenue
- PBA $7,305,229,650.00
- BIIB $9,607,500,000.00
- Revenue This Year
- PBA N/A
- BIIB N/A
- Revenue Next Year
- PBA $15.54
- BIIB N/A
- P/E Ratio
- PBA $15.61
- BIIB $13.47
- Revenue Growth
- PBA 37.18
- BIIB N/A
- 52 Week Low
- PBA $32.81
- BIIB $145.07
- 52 Week High
- PBA $43.44
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- PBA 30.57
- BIIB 31.81
- Support Level
- PBA $38.75
- BIIB $145.07
- Resistance Level
- PBA $36.99
- BIIB $149.92
- Average True Range (ATR)
- PBA 0.63
- BIIB 3.57
- MACD
- PBA -0.11
- BIIB 0.18
- Stochastic Oscillator
- PBA 24.79
- BIIB 22.27
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its assets include pipelines and gas gathering as well as assets across fractionation, storage, and propane exports.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.